This biotechnology company specialises in developing cancer medication.
Looking promising lately
1 Like
Still looking promising!
1 Like
Amazing Impulse Move
1 Like
I wonder how long this will go on for. I really hope this fuels the personalised cancer treatments they are working on. I came across this the other day also: BioNTech strengthens cancer therapy expertise with U.S. acquisition
1 Like
Why do you know
1 Like
Earnings released (8-Aug-2022)
Miss on EPS and revenue.
BioNTech GAAP EPS of €6.45 misses by €0.63
Revenue of €3.2B misses by €910M
1 Like
Will be interesting to see what happens in the market. So far it has fallen in pre trading by around 6%. I notice the trades though are small. Suggesting to me that that it is retail traders doing the selling.
Note the net profit of €1.7 billion. I also encourage anyone who is interested in this share to read the company’s original announcement:
and the full earnings presentation:
https://investors.biontech.de/static-files/52682cc7-1851-4608-8260-7a92ab0a3db6
2 Likes
For those interested in Biotech investment, including in BioNtech, there is an interesting article in the latest issue of the Economist:
(Reminder: Many public libraries in the UK make the Economist available online)
1 Like
1 Like